Navigation Links
Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents

SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plc announced today the positive results of studies of the investigational medication guanfacine extended release (GXR, previously referred to as SPD503), a selective alpha-2A-adrenoceptor agonist. These data from two short-term phase III placebo-controlled studies and two long-term phase III open-label studies, presented at the 2007 American Psychiatric Association (APA) annual meeting, demonstrated that GXR significantly improved all core symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 17 years.

"Guanfacine extended release, the first selective alpha-2A-adrenoceptor agonist to be tested in well-controlled studies as a treatment for ADHD, holds potential based on the significant improvements in ADHD symptoms documented in four studies of this investigational drug," stated co-author Joseph Biederman, M.D., lead investigator, chief of clinical and research program in pediatric psychopharmacology at Massachusetts General Hospital and professor of psychiatry at Harvard Medical School. "Moreover, these data presented at this medical conference add evidence that GXR when dosed once daily may continue to control children's ADHD symptoms for up to 24 months."

GXR, a nonstimulant, is not a controlled substance and does not appear to have a mechanism for potential abuse or dependence. Shire submitted a New Drug Application (NDA) for GXR on August 24, 2006, which is currently under FDA review. The NDA provided data on GXR 1 mg to 4 mg taken once daily for the treatment of children and adolescents with ADHD.

GXR Yielded Significant Reductions in ADHD-RS-IV Scores in Two Short-Term Trials

Results from two short-term, double-blind, randomized phase III clinical trials presented at this medical conference, demonstrated that GXR significantly controlled all core symptoms of ADHD, including inattention, hyperac tivity and impulsivity in children aged 6 to 17 years previously diagnosed with ADHD, as measured by several standardized tests when compared to placebo treatment.

In the two short-term trials, the primary endpoint was a reduction in ADHD symptoms as measured by the ADHD Rating Scale (ADHD-RS-IV). ADHD-RS-IV is a standardized, validated test for assessing symptoms of ADHD in children and for assessing their response to treatment. This scale, which contains 18 items, is based on the ADHD diagnostic criteria as defined in the APA's Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision(R).

In the first trial, 301, investigators compared 2 mg, 3 mg or 4 mg GXR doses to placebo during an eight-week treatment period. The participants randomized to GXR all began at the 1 mg dose. At weekly visits, doses were titrated in 1 mg increments over the first four weeks to achieve the randomized dose. Then, doses were tapered down weekly so that all participants randomized to GXR received the 1 mg dose at week eight.

Participants achieved overall significant mean reductions from baseline in ADHD-RS-IV total scores by study end, -16.7 points vs. -8.9 for placebo (P <.0001). Investigators observed improvement in ADHD-RS-IV scores as early as two weeks after dosing began, with significant improvement in all GXR dose groups occurring at the third week.

Effect sizes, calculated using results from the ADHD-RS-IV scores and evaluated using weight-adjusted actual doses, were 0.44 (0.01 to 0.04 mg/kg), 0.58 (0.05 to 0.08 mg/kg), 1.19 (0.09 to 0.12 mg/kg), and 1.34 (0.13 to 0.17 mg/kg). In general, effect sizes are categorized as small (0.2), medium (0.5) and large (0.8).

In the second short-term trial, 304, investigators examined 1 mg, 2 mg, 3 mg and 4 mg doses and placebo during nine weeks of treatment. During the first three weeks, patients started at 1 mg with doses escalating in once- weekly 1 mg increments to achieve the ir randomized dose at week three. Then, participants maintained their assigned dose for three weeks, followed by three weeks of decreased dosing, so that all participants were taking 1 mg doses during week nine. Participants achieved overall significant mean reductions in ADHD-RS-IV total scores by study end, -19.6 points vs. -12.2 for placebo (P <.0001).

Safety data collected in trials 301 and 304 shows that participants using GXR had adverse events which were generally mild to moderate in severity, with most common side effects being sedative in nature. In trial 301, sedation- related treatment-emergent adverse events were among the most common but were usually transient and mild or moderate in severity. Treatment related adverse events greater than 10 percent included somnolence (32 percent), fatigue (18 percent), upper abdominal pain (14 percent) and sedation (13 percent). Mean decreases observed in heart rate, and systolic and diastolic blood pressure were modest. In trial 304, common treatment related adverse events greater than 5 percent included somnolence (27 percent), fatigue (9.4 percent) and nausea (5.1 percent). Small to modest changes in blood pressure, pulse rate, and ECG were observed with GXR but were not clinically meaningful.

Long-Term ADHD Symptom Improvement with GXR

Trial 303 was a long-term, open-label, safety follow-up study of 240 participants enrolled in trial 301. The objective was to assess the long-term safety of GXR 2 mg, 3 mg, and 4 mg doses in the treatment of ADHD for up to two years. In this study, investigators documented the ability of GXR to maintain clinically meaningful efficacy of ADHD symptoms for up to 24 months of treatment. Patients were optimized to a dose ranging between 2 mg to 4 mg. Doses could be adjusted by 1 mg per monthly visit.

In this trial, the most common treatment-emergent adverse events were somnolence (30.4 percent), headache (26.3 percent), fatigue (14.2 percent) and sedation (13 .3 percent). However, somnolence, sedation and fatigue typically occurred early in the study and most resolved as treatment continued. The incidence of syncopal events was less than 1 percent. In some of the patients who did experience syncope, potential contributing factors were noted (such as dehydration, sudden change in body position, and hot environment). While small changes in average blood pressure and pulse rate occurred, cardiovascular events were uncommon.

For all doses, the mean ADHD-RS-IV total scores and subscale scores showed significant improvement from baseline to endpoint: -18.1 points on the ADHD- RS-IV total; -8.5 points on the ADHD-RS-IV hyperactive/impulsive subscale and -9.5 points on the ADHD-RS-IV inattentive subscale (P <.001).

Similar to the 303 study, the objective of the 305 open-label trial was to assess the long-term safety and efficacy of GXR for the treatment of ADHD in children and adolescents aged 6 to 17 years. During the first month of this study, investigators made weekly adjustments as needed to each participants' once-daily GXR doses from 1 mg to 4 mg for optimal dosing, as defined by 30 percent or more improvement in ADHD-RS-IV total scores.

In this trial, the most commonly reported treatment emergent adverse events greater than 10 percent were somnolence (29.9 percent), headache (19.7 percent), upper respiratory tract infection (15.1 percent), fatigue (12.4 percent) and sedation (11.2 percent). The incidence of syncopal events was less than 2 percent. As in the 303 open-label study, potential contributing factors were noted in some of the patients who did experience syncope. No clinically relevant trends in ECGs, hematologic or laboratory parameters, vital signs, urinalyses, or physical examination were seen.

Interim results from trial 305 showed that for all doses, the mean ADHD- RS-IV total scores showed significant improvement of -21.6 points from baseline to endpoint (P <.001).

About Gua nfacine Extended Release

Shire is seeking approval of GXR as monotherapy for the treatment of ADHD symptoms throughout the day in children aged 6 to 17 years, with dosage strengths of 1mg - 4 mg daily. The GXR NDA includes data from two placebo- controlled trials in children and adolescents ages 6 to 17 evaluating the compound's safety and efficacy in controlling ADHD symptoms evaluated on a once-weekly basis using the ADHD Rating Scale, which included both hyperactive/impulsive and inattentive subscales.

Guanfacine extended release is a once-daily formulation of a selective alpha-2A-adrenoceptor agonist. Unlike some other ADHD treatments, guanfacine extended release is not a central nervous system stimulant or a controlled substance and does not appear to have a mechanism for potential abuse or dependence.

It has been shown that guanfacine HCI binds selectively to the alpha 2A adrenergic cell receptors that are found throughout the part of the brain called the prefrontal cortex. The prefrontal cortex is an area of the brain associated with executive functioning, i.e., working memory, behavioral inhibition, regulation of attention, distractibility, impulsivity, and frustration tolerance.

About ADHD

Approximately 7.8 percent of all school-age children, or about 4.4 million U.S. children aged 4 to 17 years, have been diagnosed with ADHD at some point in their lives, according to the CDC. ADHD is one of the most common psychiatric disorders in children and adolescents. The disorder is also estimated to affect approximately 9.8 million adults across the U.S. based on a retrospective survey of adults aged 18 to 34, projected to the full U.S. adult population. ADHD is a neurological brain disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that is more frequent and severe than is typically observed in individuals at a comparable level of development. To be properly diagnosed with ADHD, a child needs to demonstrate at least six of nine symptoms of inattention; and/or at least six of nine symptoms of hyperactivity/impulsivity; the onset of which appears before age 7 years; that some impairment from the symptoms is present in two or more settings (e.g., at school and home); that the symptoms continue for at least six months; and that there is clinically significant impairment in social, academic or occupational functioning and the symptoms cannot be better explained by another psychiatric disorder.

Although there is no "cure" for ADHD, there are accepted treatments that specifically target its symptoms. The most common standard treatments include educational approaches, psychological or behavioral modification, and medication.

    For further information please contact:

    Porter Novelli for Shire

    Marion E. Glick


    917.301.4206 (on site at APA)

    Debra Gemme


    703.298.4030 (on site at APA)

All GXR Posters will be presented in Sails Pavilion, Upper Level in the San Diego Convention Center

APA Poster # NR659

Wednesday, May 23, 2007 at 12 p.m. PDT (3 p.m. EDT)

A Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine Extended Release in Children and Adolescents with Attention- Deficit/Hyperactivity Disorder (Trial 301)

J. Biederman, M.D.; R. Melmed, M.D.; A. Patel, M.D.; K. McBurnett, M.D.; J. Donahue, M.P.H.; A. Lyne, M.S.C.

APA Poster # NR656

Wednesday, May 23, 2007 at 12 p.m. PDT (3 p.m. EDT)

Randomized, Double-Blind Study of Guanfacine Extended Release in Children Aged 6 to 17 Years With Attention-Deficit/Hyperactivity Disorder (Trial 304)

F. Sallee, M.D.; J. McGouth; T. Wigal, Ph.D.; J. Donahue, M.P.H.; A. Lyne, M.S.C.; J. Biederman, M.D.

APA Poster # NR658

Wednesday, May 23, 2007 at 12 p.m. PDT (3 p.m. EDT)

Long-Term, Open-Label Study of Guanfacine Extended Release in Children and Adolesce nts With Attention-Deficit/Hyperactivity Disorder (Trial 303)

J. Biederman, M.D.; R. Melmed, M.D.; Anir Patel, M.D.; Keith McBurnett, M.D.; J. Donahue, M.P.H.; A. Lyne, M.S.C.

APA Poster # NR657

Wednesday, May 23, 2007 at 12 p.m. PDT (3 p.m. EDT)

Interim Results of a Long-Term, Open-Label Study of Guanfacine Extended Release in Children and Adolescents Aged 6 to 17 Years With Attention- Deficit/Hyperactivity Disorder (Trial 305)

F. Sallee, M.D.; J. Biederman, M.D.; J. McGough, M.D.; T. Wigal, Ph.D.; J. Donahue, M.P.H.; A. Lyne, M.S.C.


Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on ADHD, human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire's focused strategy is to develop and market products for specialty physicians. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company's website:


Statements included herein that are not historical facts are forward- looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties inclu de, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization; the impact of competitive products, including, but not limited to the impact of those on Shire's Attention Deficit and Hyperactivity Disorder ("ADHD") franchise; patents, including but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval, including but not limited to the expected product approval dates of SPD503 (guanfacine extended release) (ADHD) and SPD465 (extended release triple-bead mixed amphetamine salts) (ADHD); Shire's ability to secure new products for commercialization and/or development; Shire's ability to benefit from its acquisition of New River Pharmaceuticals Inc.; and other risks and uncertainties detailed from time to time in Shire plc's filings with the Securities and Exchange Commission, particularly Shire plc's Annual Report on Form 10-K for the year ended December 31, 2006.

CONTACT: Marion E. Glick, +1-212-601-8273, +1-917-301-4206, on site atAPA, or Debra Gemme, +1-212-601-8342, +1-703-298-4030, on site at APA, bothfor Shire plc

Web site:

Ticker Symbol: (NASDAQ-NMS:SHPGY),(Toronto:SHQ.)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Shire to Present New Scientific Data on ADHD Treatment Portfolio at APA Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 /PRNewswire/ ... and OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... a strategic hub service that expedites and streamlines patient ... spirometer, Spiro PD 2.0, and wellness management services.  ... a medical device used to measure lung function for ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Southern ... and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice Frueh, ... cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU School ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... annual Holly Day Market. Featuring a collection of specialty vendors and unique items from ... of personalized and quality-focused health and wellness services offered by the VNA. The ...
(Date:10/13/2017)... NJ (PRWEB) , ... October 13, 2017 , ... Global ... at scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global ... physical activity. The fun run is geared towards children of all ages; it ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
Breaking Medicine News(10 mins):